Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,intangibleAssets,capitalSurplus,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,commonStock,retainedEarnings,cash,totalCurrentLiabilities,shortLongTermDebt,propertyPlantEquipment,totalCurrentAssets,netReceivables,longTermDebt,accountsPayable,changeToLiabilities,netBorrowings,totalCashFromFinancingActivities,changeToOperatingActivities,changeInCash,totalCashFromOperatingActivities,depreciation,changeToNetincome,changeToAccountReceivables,otherCashflowsFromFinancingActivities,WC,language,region,quoteType,triggerable,quoteSourceName,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,marketCap,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,esgPopulated,tradeable,currency,priceHint,shortName,exchange,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,exchangeDataDelayedBy,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,epsTrailingTwelveMonths,marketState,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,market,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,Shares Short 4,Short Ratio 4,Short % of Float 4,Short % of Shares Outstanding 4,Shares Short (prior month ) 4,Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,longBusinessSummary,city,phone,state,country,website,maxAge,address1,fax,industry
t0,ENZC,-717021.0,2438670080,,,-593212,,-593212,585413,0,-587847,-587847,,-5365,,,,0,0,587847,0,-5365,,-593212,-593212,5241.0,7894412.0,733906.0,-711780.0,301729.0,22126.0,56194.0,-8662386.0,5760.0,659972.0,24188.0,9850.0,7035.0,1275.0,73934.0,140855.0,0.0,77884.0,77884.0,8410.0,-2322.0,-80206.0,2434.0,502162.0,,,-652937.0,en-US,US,EQUITY,False,Delayed Quote,0.13,1630508592,-0.010600001,0.143,0.145,0.1275,9448152,-0.094071195,-0.41982725,317027104,-0.20537123,15,America/New_York,EDT,-14400000,False,False,USD,4,ENZOLYTICS INC,PNK,-0.633,0.16421944,-0.034219444,-0.20837633,0.22407119,0,finmb_42996625,Other OTC,Enzolytics Inc.,USD,25065320,16227958,0.12959999,323.99997,4.0E-4 - 0.958,-0.828,-0.8643006,0.0004,0.958,-4.758,REGULAR,-7.539119,0.1275 - 0.145,0.1406,us_market,-2.2,,,0.958,0.0004,0.1642,0.2241,25.07M,16.23M,2.44B,,,0.00%,0.05%,,,,,,,,,,,0.00%,,,1:500,"Feb 06, 2013","Dec 30, 2011","Mar 30, 2012",0.00%,"-1,924.25%",-704.70%,,46.59k,0.22,,52.81k,-886.77k,-1.03M,-4.7580,,5.76k,0,233.12k,,0.01,-0.63,-621.04k,151.19k,Value,75074,Healthcare,"Enzolytics, Inc., a drug development company, focuses to the commercialization of its proprietary proteins for the treatment of debilitating infectious diseases. Its patented anti-HIV therapeutics and a proprietary methodology for producing human IgG1 monoclonal antibodies for treating infectious diseases with non-toxic passive immunotherapy. The company has clinically tested anti-HIV therapeutics. In addition, it has created a proprietary cell line that produces human monoclonal antibodies that target and neutralizes the HIV virus. Enzolytics Inc. is based in Plano, Texas.",Plano,972 292 9414,TX,United States,http://enzolytics.com,86400,2000 North Central Expressway,631 256 5750,Biotechnology
t-1,ENZC,-736350.0,2438670080,,,-221241,,-221241,226287,15350,-214028,-214028,,-7213,,,,0,15350,229378,0,-7213,,-221241,-221241,45771.0,9114014.0,802632.0,-690579.0,222167.0,112053.0,2959.0,-9807552.0,7900.0,778212.0,93726.0,16882.0,49400.0,1500.0,24420.0,159967.0,4694.0,103830.0,103835.0,110777.0,3971.0,-99859.0,3752.0,-190875.0,450.0,5.0,-728812.0,en-US,US,EQUITY,False,Delayed Quote,0.13,1630508592,-0.010600001,0.143,0.145,0.1275,9448152,-0.094071195,-0.41982725,317027104,-0.20537123,15,America/New_York,EDT,-14400000,False,False,USD,4,ENZOLYTICS INC,PNK,-0.633,0.16421944,-0.034219444,-0.20837633,0.22407119,0,finmb_42996625,Other OTC,Enzolytics Inc.,USD,25065320,16227958,0.12959999,323.99997,4.0E-4 - 0.958,-0.828,-0.8643006,0.0004,0.958,-4.758,REGULAR,-7.539119,0.1275 - 0.145,0.1406,us_market,-2.2,,,0.958,0.0004,0.1642,0.2241,25.07M,16.23M,2.44B,,,0.00%,0.05%,,,,,,,,,,,0.00%,,,1:500,"Feb 06, 2013","Dec 30, 2011","Mar 30, 2012",0.00%,"-1,924.25%",-704.70%,,46.59k,0.22,,52.81k,-886.77k,-1.03M,-4.7580,,5.76k,0,233.12k,,0.01,-0.63,-621.04k,151.19k,Value,75074,Healthcare,"Enzolytics, Inc., a drug development company, focuses to the commercialization of its proprietary proteins for the treatment of debilitating infectious diseases. Its patented anti-HIV therapeutics and a proprietary methodology for producing human IgG1 monoclonal antibodies for treating infectious diseases with non-toxic passive immunotherapy. The company has clinically tested anti-HIV therapeutics. In addition, it has created a proprietary cell line that produces human monoclonal antibodies that target and neutralizes the HIV virus. Enzolytics Inc. is based in Plano, Texas.",Plano,972 292 9414,TX,United States,http://enzolytics.com,86400,2000 North Central Expressway,631 256 5750,Biotechnology
t-2,ENZC,-709856.0,2438670080,,,-447627,,-447627,281552,6217,-277769,-277769,,-7483,,,,0,6217,283986,0,-169858,,-447627,-447627,46518.0,8920253.0,800234.0,-663338.0,,136896.0,2720.0,-9586311.0,9202.0,775814.0,93726.0,19226.0,71152.0,1950.0,24420.0,159967.0,-2347.0,142302.0,142302.0,89147.0,2639.0,-139663.0,2434.0,217875.0,855.0,5.0,-704662.0,en-US,US,EQUITY,False,Delayed Quote,0.13,1630508592,-0.010600001,0.143,0.145,0.1275,9448152,-0.094071195,-0.41982725,317027104,-0.20537123,15,America/New_York,EDT,-14400000,False,False,USD,4,ENZOLYTICS INC,PNK,-0.633,0.16421944,-0.034219444,-0.20837633,0.22407119,0,finmb_42996625,Other OTC,Enzolytics Inc.,USD,25065320,16227958,0.12959999,323.99997,4.0E-4 - 0.958,-0.828,-0.8643006,0.0004,0.958,-4.758,REGULAR,-7.539119,0.1275 - 0.145,0.1406,us_market,-2.2,,,0.958,0.0004,0.1642,0.2241,25.07M,16.23M,2.44B,,,0.00%,0.05%,,,,,,,,,,,0.00%,,,1:500,"Feb 06, 2013","Dec 30, 2011","Mar 30, 2012",0.00%,"-1,924.25%",-704.70%,,46.59k,0.22,,52.81k,-886.77k,-1.03M,-4.7580,,5.76k,0,233.12k,,0.01,-0.63,-621.04k,151.19k,Value,75074,Healthcare,"Enzolytics, Inc., a drug development company, focuses to the commercialization of its proprietary proteins for the treatment of debilitating infectious diseases. Its patented anti-HIV therapeutics and a proprietary methodology for producing human IgG1 monoclonal antibodies for treating infectious diseases with non-toxic passive immunotherapy. The company has clinically tested anti-HIV therapeutics. In addition, it has created a proprietary cell line that produces human monoclonal antibodies that target and neutralizes the HIV virus. Enzolytics Inc. is based in Plano, Texas.",Plano,972 292 9414,TX,United States,http://enzolytics.com,86400,2000 North Central Expressway,631 256 5750,Biotechnology
t-3,ENZC,-619314.0,2438670080,,,-5408456,,-5408456,-423178,11585,-794957,-794957,,-43590,,,,0,11585,806542,0,-4613499,,-5408456,-5408456,47269.0,8756655.0,724979.0,-572045.0,,152934.0,2568.0,-9331268.0,1290.0,676743.0,91568.0,21570.0,84095.0,2805.0,48236.0,162314.0,34418.0,39013.0,39013.0,-36114.0,1234.0,-37779.0,3095.0,5365172.0,4106.0,5.0,-592648.0,en-US,US,EQUITY,False,Delayed Quote,0.13,1630508592,-0.010600001,0.143,0.145,0.1275,9448152,-0.094071195,-0.41982725,317027104,-0.20537123,15,America/New_York,EDT,-14400000,False,False,USD,4,ENZOLYTICS INC,PNK,-0.633,0.16421944,-0.034219444,-0.20837633,0.22407119,0,finmb_42996625,Other OTC,Enzolytics Inc.,USD,25065320,16227958,0.12959999,323.99997,4.0E-4 - 0.958,-0.828,-0.8643006,0.0004,0.958,-4.758,REGULAR,-7.539119,0.1275 - 0.145,0.1406,us_market,-2.2,,,0.958,0.0004,0.1642,0.2241,25.07M,16.23M,2.44B,,,0.00%,0.05%,,,,,,,,,,,0.00%,,,1:500,"Feb 06, 2013","Dec 30, 2011","Mar 30, 2012",0.00%,"-1,924.25%",-704.70%,,46.59k,0.22,,52.81k,-886.77k,-1.03M,-4.7580,,5.76k,0,233.12k,,0.01,-0.63,-621.04k,151.19k,Value,75074,Healthcare,"Enzolytics, Inc., a drug development company, focuses to the commercialization of its proprietary proteins for the treatment of debilitating infectious diseases. Its patented anti-HIV therapeutics and a proprietary methodology for producing human IgG1 monoclonal antibodies for treating infectious diseases with non-toxic passive immunotherapy. The company has clinically tested anti-HIV therapeutics. In addition, it has created a proprietary cell line that produces human monoclonal antibodies that target and neutralizes the HIV virus. Enzolytics Inc. is based in Plano, Texas.",Plano,972 292 9414,TX,United States,http://enzolytics.com,86400,2000 North Central Expressway,631 256 5750,Biotechnology
